News >

FDA Approves Two New Indications for Pembrolizumab in Advanced Melanoma

Jason M. Broderick @jasoncology
Published: Friday, Dec 18, 2015

Dr. Roger Perlmutter

Roger M. Perlmutter, MD, PhD

The FDA has expanded the approval for single-agent pembrolizumab (Keytruda) to include the frontline treatment of patients with advanced melanoma regardless of BRAF status, based on a substantial improvement in progression-free and overall survival compared with ipilimumab (Yervoy) in the phase III KEYNOTE-006 trial.1

In the study, which compared 2 pembrolizumab regimens with ipilimumab, the PD-1 inhibitor reduced the risk of disease progression by >40% and the risk of death by >30%.

“As recently as five years ago, there were few treatment options for patients suffering from advanced melanoma,” Roger M. Perlmutter, MD, PhD, president, Merck Research Laboratories, the developer of the PD-1 inhibitor, said in a statement. “Today’s news is another exciting milestone for Keytruda and for patients with this disease."

In addition to the frontline approval, the FDA also updated the label for pembrolizumab to include the treatment of patients with ipilimumab-refractory melanoma, based on a greater than 43% reduction in the risk of death versus chemotherapy in the phase II KEYNOTE-002 trial.2

“This growing body of evidence in patients with advanced melanoma supports the expanded indication for Keytruda,” Omid Hamid, MD, director of the Melanoma Center at The Angeles Clinic and Research Institute, said in a statement. “This approval highlights the importance of Keytruda for advanced melanoma, where we are in need of additional treatment options.”

KEYNOTE-006 included 834 patients with unresectable stage III or IV advanced melanoma who had received no more than 1 prior systemic therapy. Among the overall patient population, 65.8% had not previously received systemic treatment for advanced melanoma and 68.7% had an ECOG performance status of 0.

Patients were randomized in a 1:1:1 ratio to receive 4 cycles of ipilimumab at 3 mg/kg every 3 weeks (n = 278), 10 mg/kg of pembrolizumab every 3 weeks (n = 277), or 10 mg/kg of pembrolizumab every 2 weeks (n = 279). Both doses of pembrolizumab were higher than the previously approved FDA regimen of 2 mg/kg every 3 weeks. However, the frontline approval for pembrolizumab is also for 2 mg/kg every 3 weeks.

Patient response in KEYNOTE-006 was assessed at week 12 and every 6 weeks thereafter by RECIST 1.1. The median follow-up was 7.9 months (range, 6.1-11.5). 

At a 6-month assessment, the progression-free survival (PFS) rate with pembrolizumab was 47.3% and 46.4% in the 2- and 3-week arms respectively, compared with 26.5% for the ipilimumab arm (HR, 0.58; P <.001). Median PFS was 5.5, 4.1, and 2.8 months, respectively. The PFS benefit with pembrolizumab over ipilimumab was observed regardless of patients’ PD-L1 status.

The 9-month PFS rates were 40% and 42% compared with 16%, in the 2-week, 3-week, and ipilimumab arms, respectively, according to Merck, which develops pembrolizumab.

The 1-year overall survival (OS) rate was 74.1% for the 2-week pembrolizumab arm versus 58.2% for those receiving ipilimumab (HR, 0.63; 95% CI, 0.47-0.83; P<.0005). In the 3-week pembrolizumab group, the 1-year OS rate was 68.4% (HR vs ipilimumab, 0.69; 95% CI, 0.52-0.90; P = .0036).

The objective response rates (ORR) were 33.7% and 32.9%, in the 2- and 3-week arms. In the ipilimumab arm, the ORR was 11.9%. Complete response rates were 5.0%, 6.1%, and 1.4%, respectively.

The toxicity profiles of the agents were consistent with other reported studies of the two checkpoint agents. Although pembrolizumab was administered for a longer duration, rates of grade 3-5 adverse events (AEs) were lower with both the 2- and 3-week doses versus ipilimumab at 13.3% and 10.1% versus 19.9%, respectively. Discontinuation rates were also lower with pembrolizumab, at 4.0%, 6.9%, and 9.4%, respectively.

The most frequently reported all-grade AEs in the 2- and 3-week pembrolizumab arms were fatigue (20.9%, 19.1%), diarrhea (16.9%, 14.4%), rash (14.7%, 13.4%), and pruritus (14.4%, 14.1%). All grade 3/4 AEs occurred in <1% of the pembrolizumab arms, except diarrhea (2.5% and 1.1%).

In the ipilimumab arm, the most common all-grade AEs were pruritus (25.4%), diarrhea (22.7%), fatigue (15.2%), and rash (14.5%). Grade 3/5 AEs occurred in <1% patients in the ipilimumab arm, except diarrhea (3.1%) and fatigue (1.2%). There was 1 patient death associated with ipilimumab treatment.

"Data supporting the approval emerged from a large and diverse patient population, including patients with very advanced disease and patients whose tumors carried BRAF mutations, thus demonstrating both the breadth of our clinical development program for Keytruda, and the potential of Keytruda to extend the lives of those afflicted with this grievous malignancy,” said Perlmutter.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication